Sunitinib induced nephrotic syndrome and thrombotic microangiopathy

Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor of targets such as vascular endothelial growth factor and platelet derived growth factor receptor. It is used for the treatment of metastatic renal cell carcinoma (RCC). Use of sunitinib has been associated with renal dysfunction and nephrotic syndrome. However, simultaneous occurrence of nephrotic syndrome and renal dysfunction in a patient treated with sunitinib is rare. We report a case of metastatic RCC treated with sunitinib for 22 months who presented with nephrotic syndrome and renal dysfunction. Renal biopsy was diagnostic of thrombotic microangiopathy with diffuse effacement of podocytic foot process.

[1]  A case of membranous glomerulonephritis associated with adenocarcinoma of pancreas. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  M. Marrero,et al.  Vascular Endothelial Growth Factor Signals Endothelial Cell Production of Nitric Oxide and Prostacyclin through Flk-1/KDR Activation of c-Src* , 1999, The Journal of Biological Chemistry.

[3]  T. Wakayama,et al.  Downregulation of Vascular Endothelial Growth Factor and Its Receptors in the Kidney in Rats with Puromycin Aminonucleoside Nephrosis , 2001, Nephron.

[4]  A. Tobar,et al.  Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease? , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[6]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[7]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[8]  D. Nochy,et al.  Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. , 2007, The Lancet. Oncology.

[9]  H. Gelderblom,et al.  Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[11]  G. Demetri,et al.  A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. , 2008, Journal of the National Cancer Institute.

[12]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[13]  M. Gordon,et al.  Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .

[14]  D. Nochy,et al.  VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.

[15]  C. Robert,et al.  Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  J. Marsh,et al.  Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 , 2009 .

[18]  Nephrotic Syndrome and Acute Renal Failure Apparently Induced by Sunitinib , 2009, Case Reports in Oncology.

[19]  R. Selgas,et al.  Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  M. Schiffer,et al.  Renal Involvement in Preeclampsia: Similarities to VEGF Ablation Therapy , 2010, Journal of pregnancy.